COMP <GO>
KIDS vs LLY // RSI-14 & 200D SMA MOMENTUM
OrthoPediatrics Corp. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: KIDS 1
— LLY 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KIDS
LAST: $31.52 (+2.34%) • MKT CAP: $823.0M
rsi-technicals
79.0
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
rsi-technicals
66.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KIDS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KIDS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.10% | 83.64% | -10.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.30% | 32.36% | -39.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.94% | 2.30% | -4.24 | LLY | /fcf-yield <GO> |
| Operating Margin | -16.60% | 40.21% | -56.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | -16.80% | 31.90% | -48.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 45.51% | -30.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.00 | 9.29 | -6.29 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 79.0 | 66.6 | +12.40 | KIDS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $823.0M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KIDS REV | LLY REV | KIDS GROSS % | LLY GROSS % | KIDS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $236.3M | $65.18B | 73.1% | 83.0% | -$16.0M | $16.81B |
| FY 2024 | $204.7M | $45.04B | 72.6% | 81.3% | -$41.3M | $8.82B |
| FY 2023 | $148.7M | $34.12B | — | 79.3% | -$27.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KIDS // BETA —
LLY // BETA 0.51